Kovesdy CP. Epidemiology of chronic kidney disease: An update 2022. Kidney Int Suppl. 2011;2022(12):7–11.

Google Scholar 

Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE. 2014;9:e84943.

Article  PubMed  PubMed Central  Google Scholar 

Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: A review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119:2017–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The Impact of CKD anaemia on patients: Incidence, risk factors, and clinical outcomes-A systematic literature review. Int J Nephrol. 2020;2020:7692376.

Article  PubMed  PubMed Central  Google Scholar 

Locatelli F, Minutolo R, De Nicola L, Del Vecchio L. Evolving strategies in the treatment of anaemia in chronic kidney disease: The HIF-prolyl hydroxylase inhibitors. Drugs. 2022;82:1565–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol. 2020;31:456–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67:912–24.

Article  CAS  PubMed  Google Scholar 

Ogawa C, Tsuchiya K, Maeda K. Hypoxia-inducible factor prolyl hydroxylase inhibitors and iron metabolism. Int J Mol Sci. 2023;24:3037.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, et al. Novel anemia therapies in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023;104:655–80.

Article  PubMed  Google Scholar 

Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant. 2010;25:3701–6.

Article  CAS  PubMed  Google Scholar 

Zheng L, Tian J, Liu D, Zhao Y, Fang X, Zhang Y, et al. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:919–32.

Article  CAS  PubMed  Google Scholar 

Ichii M, Mori K, Miyaoka D, Sonoda M, Tsujimoto Y, Nakatani S, et al. Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. BMC Nephrol. 2021;22:104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tokuyama A, Kadoya H, Obata A, Obata T, Sasaki T, Kashihara N. Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021;14:1472–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kouki Y, Okada N, Saga K, Ozaki M, Saisyo A, Kitahara T. Disproportionality analysis on hypothyroidism with roxadustat using the Japanese Adverse Drug Event Database. J Clin Pharmacol. 2023;63:1141–6.

Article  CAS  PubMed  Google Scholar 

Tanaka H, Tani A, Onoda T, Ishii T. Hypoxia-inducible factor prolyl hydroxylase inhibitors and hypothyroidism: An analysis of the Japanese Pharmacovigilance Database. In Vivo. 2024;38:917–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haraguchi T, Hamamoto Y, Kuwata H, Yamazaki Y, Nakatani S, Hyo T, et al. Effect of roxadustat on thyroid function in patients with renal anemia. J Clin Endocrinol Metab. 2023;109:e69–75.

Article  PubMed  Google Scholar 

Ma Y, Freitag P, Zhou J, Brune B, Frede S, Fandrey J. Thyroid hormone induces erythropoietin gene expression through augmented accumulation of hypoxia-inducible factor-1. Am J Physiol Regul Integr Comp Physiol. 2004;287:R600–7.

Article  CAS  PubMed  Google Scholar 

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLOS Med. 2009;6:e1000100.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. Robins-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

Article  PubMed  PubMed Central  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

Article  CAS  PubMed  Google Scholar 

Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30:1665–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6:624–35.

Article  PubMed  Google Scholar 

Charytan C, Manllo-Karim R, Martin ER, Steer D, Bernardo M, Dua SL, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021;6:1829–39.

Article  PubMed  PubMed Central  Google Scholar 

Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP, et al. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: Results from the randomized phase 3 Rockies study. J Am Soc Nephrol. 2022;33:850–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng X, Jin Y, Xu T, Xu H, Zhu S. Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: A cohort study. Ren Fail. 2023;45:2199093.

Article  PubMed  PubMed Central  Google Scholar 

Cheng Y, Xiang Q, Cao T, Tang F, Chen J, Qi D, et al. Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients. Nephrol Dial Transplant. 2023;38:1567–70.

Article  CAS  PubMed  Google Scholar 

Yao B, Wei Y, Zhang S, Tian S, Xu S, Wang R, et al. Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance. iScience. 2019;20:489–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. 2012;122:3035–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Narasaki Y, Sohn P, Rhee CM. The interplay between thyroid dysfunction and kidney disease. Semin Nephrol. 2021;41:133–43.

Article  PubMed  PubMed Central  Google Scholar